Fundraising Fox
Immuneering
NASDAQ: IMRXCambridge, US · Founded 2008 · Delaware corporation · 63 employees on LinkedIn · 3 known investors
Find your way into Immuneering
Sign up to see every warm intro you have to Immuneering
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Immuneering team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Immuneering develops Deep Cyclic Inhibitors, a class of oncology medicines designed to pulse dosing faster than cancer's adaptive mechanisms to limit resistance and reduce side effects. The company targets more durable tumor control and improved tolerability for cancer patients.
Founders & leadership
Immuneering was founded in 2008 by Benjamin J. Zeskind.
BJ
Benjamin J. ZeskindFounder
HE
Harold E. BrakewoodChief Business OfficerHarold E. Brakewood is Chief Business Officer at Immuneering, which develops oncology medicines designed to improve tumor control and tolerability in cancer patients. His background includes C-suite leadership roles focused on business development and commercialization across oncology, rare diseases, and other therapeutic areas.
BH
Brett HallCSOBrett Hall serves as Chief Scientific Officer of Immuneering, which develops Deep Cyclic Inhibitors for oncology treatment. He brings drug discovery and development experience across immunology and oncology, including preclinical and clinical pharmacology and biomarker development.
MD
Michael D. BookmanChief Legal Officer & SecretaryChief Legal Officer and Secretary at Immuneering, which develops oncology medicines. Experienced in business and startup advisory.
IM
Igor MatushanskyChief Medical Officer
MM
Mallory MoralesSVP Finance and Chief Accounting OfficerMallory Morales is a CPA and senior finance executive with 20 years of experience in high-growth organizations, including roles ranging from startups to multi-billion-dollar enterprises. Her expertise spans corporate finance, capital markets, governance and compliance, and process transformation, with experience in financial reporting, treasury management, IPOs, M&A, and SEC compliance.
LR
Leah R. NeufeldChief People OfficerLeah R. Neufeld is Chief People Officer at Immuneering, an oncology biotech company. She brings human resources experience across large pharmaceutical and biotech organizations, with background spanning oncology, neurology, cardiology, gene therapy, and manufacturing operations.
JK
Joseph KekstNamed on SEC filing
Board
PF
Peter FeinbergBoard director
LB
Laurie B. KeatingBoard director
RC
Robert CarpenterBoard director
TJ
Thomas J. SchallBoard director
Investors · 3
Rock Springs CapitalreportedBaltimore
How we know: the S-1 prospectus · Not right? Tell us
T. Rowe PricereportedBaltimore
How we know: the S-1 prospectus · Not right? Tell us
Also in the syndicate · 1
Boxcar PMJ LLClead
Reported raises · per SEC filings
Form D private placements$82.2M disclosed across 3 rounds · 2020–2025
▶$25MraisedSep 2025 · 9 investors · BiotechnologyRule 506(b)
▶$25MraisedSep 2025 · 9 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Benjamin J. ZeskindExecutive Officer, Director
- Laurie B. KeatingDirector
- Robert CarpenterDirector
- Thomas J. SchallDirector
- Diana F. HausmanDirector
- Peter FeinbergDirector
- Offering amount
- $25M
- Amount sold
- $25M
- First sale
- Aug 2025
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$37.2MraisedJan 2021 · 39 investors · OtherRule 506(b)
▶$37.2MraisedJan 2021 · 39 investors · Other
Rule 506(b)Officers, directors & promoters on the filing
- Benjamin J. ZeskindExecutive Officer, Director
- Robert CarpenterDirector
- Joseph KekstDirector
- Andrew PhillipsDirector
- Offering amount
- $62M
- Amount sold
- $37.2M
- First sale
- Dec 2020
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$20MraisedJan 2020 · 67 investors · PharmaceuticalsRule 506(b)
▶$20MraisedJan 2020 · 67 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Robert CarpenterDirector
- Benjamin J. ZeskindExecutive Officer, Director
- Joseph KekstDirector
- Offering amount
- $20M
- Amount sold
- $20M
- First sale
- Jan 2020
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Related companies · 1
Companies working in the same space as Immuneering.
In the news
Frequently asked questions
- What does Immuneering do?
- Immuneering develops Deep Cyclic Inhibitors, a class of oncology medicines designed to pulse dosing faster than cancer's adaptive mechanisms to limit resistance and reduce side effects. The company targets more durable tumor control and improved tolerability for cancer patients.
- Who founded Immuneering?
- Immuneering was founded by Benjamin J. Zeskind in 2008.
- Who are Immuneering's investors?
- Immuneering's investors include Rock Springs Capital, T. Rowe Price.
- How much funding has Immuneering raised?
- Immuneering has disclosed $82.2M raised across 3 rounds.
- Where is Immuneering headquartered?
- Immuneering is headquartered in Cambridge, US.